{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Dominari Holdings, Inc.
Dominari Holdings Hits 52-Week Low at $2.82 Amid Market Challenges
Dominari Holdings, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.82. With a market cap of USD 48 million, the company faces challenges, including a negative return on equity and a low price-to-book ratio, while being classified as loss-making.
Dominari Holdings Hits 52-Week Low at $2.84 Amid Market Challenges
Dominari Holdings, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, contrasting with its previous high. The company has a market cap of USD 56 million, a negative return on equity, and a low price-to-book ratio, alongside a notable dividend yield.
Dominari Holdings Hits 52-Week Low at $2.85 Amid Market Challenges
Dominari Holdings, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, recently hit a 52-week low of USD 2.85, contrasting with its high of USD 8.40. With a market cap of USD 56 million, the company faces challenges, including negative return on equity and a low price-to-book ratio, while offering a notable dividend yield of 9.46%.
Dominari Holdings, Inc. Stock Plummets to New 52-Week Low at $2.90
Dominari Holdings, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting its challenging market position. With a market cap of USD 56 million, the company shows negative return on equity and a low price-to-book ratio, indicating potential undervaluation amid financial struggles.
Dominari Holdings Hits New 52-Week Low at $3.00 Amid Market Challenges
Dominari Holdings, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.00. With a market cap of USD 56 million, the company faces challenges reflected in its negative return on equity and low price-to-book ratio, while offering a notable dividend yield.
Is Dominari Holdings, Inc. technically bullish or bearish?
As of September 9, 2025, Dominari Holdings, Inc. shows a mildly bullish technical trend, supported by bullish daily moving averages and weekly MACD, but caution is advised due to a bearish monthly RSI.
Is Dominari Holdings, Inc. overvalued or undervalued?
As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to poor financial metrics, including a Price to Book Value of 1.87 and a troubling ROCE of -169.94%, with its stock price of 6.33 significantly below its 52-week high of 13.58.
Is Dominari Holdings, Inc. technically bullish or bearish?
As of June 2, 2025, Dominari Holdings, Inc. shows a mildly bullish trend driven by monthly bullish MACD and KST indicators, though conflicting weekly signals suggest mixed conditions.
Is Dominari Holdings, Inc. overvalued or undervalued?
As of November 6, 2023, Dominari Holdings, Inc. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 1.87 and a significantly negative Return on Capital Employed of -169.94%, despite strong year-to-date stock returns of 451.61%.
Who are in the management team of Dominari Holdings, Inc.?
As of March 2022, the management team of Dominari Holdings, Inc. includes Dr. Robert Vander Zanden (Independent Chairman), Mr. Anthony Hayes (CEO and multiple officer roles), and Directors Mr. Robert Dudley, Mr. Gregory Blattner, Mr. Tim Ledwick, and Mr. Paul LeMire. The team features a blend of executive leadership and independent directors.
What does Dominari Holdings, Inc. do?
Dominari Holdings, Inc. is a biotechnology company focused on developing small-molecule anti-cancer therapeutics. As of March 2025, it reported net sales of $8 million and a net loss of $32 million, with a market cap of $74.11 million.
How big is Dominari Holdings, Inc.?
As of Jun 18, Dominari Holdings, Inc. has a market capitalization of 74.11 million and reported net sales of 24.88 million, with a net profit loss of 41.75 million over the latest four quarters. Shareholder's funds are at 39.85 million, and total assets are 48.01 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
